Abstract:BackgroundIn order to improve assessment and outcome prediction in patients suffering from traumatic brain injury (TBI), cerebral protein levels in serum have been suggested as biomarkers of injury. However, despite much investigation, biomarkers have yet to reach broad clinical utility in TBI. This study is a 9-year follow-up and clinical experience of the two most studied proteins, neuron-specific enolase (NSE) and S100B, in a neuro-intensive care TBI population. Our aims were to investigate to what extent NSE and S100B, independently and in combination, could predict outcome, assess injury severity, and to investigate if the biomarker levels were influenced by extracranial factors.MethodsAll patients treated at the neuro-intensive care unit at Karolinska University Hospital, Stockholm, Sweden between 2005 and 2013 with at least three measurements of serum S100B and NSE (sampled twice daily) were retrospectively included. In total, 417 patients fulfilled the criteria. Parameters were extracted from the computerized hospital charts. Glasgow Outcome Score (GOS) was used to assess long-term functional outcome. Univariate, and multivariate, regression models toward outcome and what explained the high levels of the biomarkers were performed. Nagelkerke’s pseudo-R2 was used to illustrate the explained variance of the different models. A sliding window assessed biomarker correlation to outcome and multitrauma over time.ResultsS100B was found a better predictor of outcome as compared to NSE (area under the curve (AUC) samples, the first 48 hours had Nagelkerke’s pseudo-R2 values of 0.132 and 0.038, respectively), where the information content of S100B peaks at approximately 1 day after trauma. In contrast, although both biomarkers were independently correlated to outcome, NSE had limited additional predictive capabilities in the presence of S100B in multivariate models, due to covariance between the two biomarkers (correlation coefficient 0.673 for AUC 48 hours). Moreover, NSE was to a greater extent correlated to multitrauma the first 48 hours following injury, whereas the effect of extracerebral trauma on S100B levels appears limited to the first 12 hours.ConclusionsWhile both biomarkers are independently correlated to long-term functional outcome, S100B is found a more accurate outcome predictor and possibly a more clinically useful biomarker than NSE for TBI patients.

Elevation of neuron-specific enolase and S-100β protein level in experimental acute spinal cord injury

The Prognostic Value of Serum Neuron Specific Enolase (NSE) and S100B Level in Patients of Acute Spinal Cord Injury

S-100B and Neuron Specific Enolase in Outcome Prediction of Severe Head Injury

Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury

Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity

Serum and Cerebrospinal Fluid Tau Protein Level As Biomarkers for Evaluating Acute Spinal Cord Injury Severity and Motor Function Outcome

The Dynamic Change of Neuron Specific Enolase Following Acute Brain Injury in Rats

Clinical Significance of Neuron Specific Enolase and S100 Beta Protein in Intracranial Infection and Brain Injury.

Temporal–spatial Expression of ENOLASE after Acute Spinal Cord Injury in Adult Rats

Neuron specific enolase: a promising therapeutic target in acute spinal cord injury

Research of Serum Neuron-specific Enolase to Evaluate the Prognosis of Severe Head Injury

876 Neuron Specific Enolase and S-100 Protein in Sepsis Associated Encephalopathy (SAE)

Measurement of serum neuron-specific enolase levels in patients with acute stroke

Biomarkers for Predicting the Severity of Spinal Cord Injury by Proteomic Analysis

Significance of serum neuron-specific enolase in assessment of severity of brain damage and its correlation with Glascow Coma Scale score

Prognosticating acute traumatic spinal cord injury using Neurofilament (NF), Neuron Specific Enolase (NSE), Matrix Metalloproteinases (MMPs), and S-100B as biomarkers

Serum Neuron Specific Enolase and Matrix Metalloproteinases in Patients with Severe Traumatic Brain Injury and the Clinical Significance

Relationship between cerebrospinal fluidα-Synuclein and prognosis of patients with traumatic brain injury

Evaluation of severe brain injury prognosis by neuron-specific enolase, myelin basic protein

Identification of Differentially Expressed Proteins in Rats with Early Subacute Spinal Cord Injury Using an Itraq-Based Quantitative Analysis.

Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest